HHM Wealth Advisors LLC Buys 154 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

HHM Wealth Advisors LLC lifted its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 118.5% during the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 284 shares of the biopharmaceutical company’s stock after buying an additional 154 shares during the quarter. HHM Wealth Advisors LLC’s holdings in Gilead Sciences were worth $26,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in the business. Bellevue Group AG grew its position in shares of Gilead Sciences by 18.2% during the third quarter. Bellevue Group AG now owns 46,027 shares of the biopharmaceutical company’s stock valued at $3,859,000 after purchasing an additional 7,093 shares in the last quarter. Quantinno Capital Management LP increased its stake in Gilead Sciences by 149.5% in the 3rd quarter. Quantinno Capital Management LP now owns 81,620 shares of the biopharmaceutical company’s stock worth $6,843,000 after acquiring an additional 48,910 shares during the last quarter. IRON Financial LLC purchased a new stake in shares of Gilead Sciences during the 3rd quarter worth approximately $830,000. Capital Investment Advisors LLC boosted its position in shares of Gilead Sciences by 2.6% during the 4th quarter. Capital Investment Advisors LLC now owns 387,492 shares of the biopharmaceutical company’s stock valued at $35,793,000 after acquiring an additional 9,791 shares during the last quarter. Finally, Wealth Enhancement Advisory Services LLC grew its holdings in shares of Gilead Sciences by 12.9% in the third quarter. Wealth Enhancement Advisory Services LLC now owns 323,011 shares of the biopharmaceutical company’s stock valued at $27,081,000 after purchasing an additional 36,895 shares in the last quarter. Institutional investors own 83.67% of the company’s stock.

Gilead Sciences Trading Up 1.2 %

GILD stock opened at $98.38 on Tuesday. The company has a quick ratio of 1.10, a current ratio of 1.26 and a debt-to-equity ratio of 1.24. The company has a market cap of $122.61 billion, a price-to-earnings ratio of 1,093.11, a PEG ratio of 1.37 and a beta of 0.18. The business has a fifty day simple moving average of $92.42 and a 200-day simple moving average of $85.96. Gilead Sciences, Inc. has a 52 week low of $62.07 and a 52 week high of $99.45.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share for the quarter, beating analysts’ consensus estimates of $1.58 by $0.44. The firm had revenue of $7.55 billion for the quarter, compared to analysts’ expectations of $7.01 billion. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. Gilead Sciences’s revenue was up 7.0% compared to the same quarter last year. During the same period in the previous year, the company posted $2.29 earnings per share. On average, equities research analysts expect that Gilead Sciences, Inc. will post 4.34 EPS for the current year.

Insider Buying and Selling at Gilead Sciences

In other news, insider Merdad Parsey sold 25,590 shares of the company’s stock in a transaction on Wednesday, November 6th. The shares were sold at an average price of $91.50, for a total value of $2,341,485.00. Following the completion of the transaction, the insider now directly owns 99,599 shares in the company, valued at approximately $9,113,308.50. This represents a 20.44 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Andrew D. Dickinson sold 2,500 shares of Gilead Sciences stock in a transaction on Wednesday, January 15th. The stock was sold at an average price of $91.35, for a total transaction of $228,375.00. Following the sale, the chief financial officer now directly owns 129,873 shares in the company, valued at $11,863,898.55. This trade represents a 1.89 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 598,414 shares of company stock valued at $55,953,200 over the last three months. 0.29% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on GILD shares. Wells Fargo & Company increased their price objective on shares of Gilead Sciences from $100.00 to $105.00 and gave the company an “overweight” rating in a research report on Thursday, November 7th. Royal Bank of Canada restated a “sector perform” rating and set a $84.00 price objective on shares of Gilead Sciences in a research report on Monday. Piper Sandler lifted their target price on Gilead Sciences from $95.00 to $105.00 and gave the stock an “overweight” rating in a report on Thursday, November 7th. Maxim Group downgraded Gilead Sciences from a “buy” rating to a “hold” rating in a research report on Friday, November 8th. Finally, Daiwa America upgraded shares of Gilead Sciences to a “hold” rating in a research report on Monday, November 18th. Eleven research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and four have given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $98.39.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.